Jörn M. Schattenberg

Author

Johannes Gutenberg University Mainz ORCID

Also Known As

Anita Hill, Detlef Schuppan, J M Schattenberg, J SCHATTENBERG, J Schattenberg, J Schnau, J. M. Schattenberg, J. Schattenberg, J.M. Schattenberg, J. M. Schattenberg

801

Publications

31K

Citations

H-Index

158

Concepts

All Affiliations

Johannes Gutenberg University Mainz University Medical Center of the Johannes Gutenberg University Mainz Newcastle University University of Turin Saarland University

About

Jörn M. Schattenberg is an author at Johannes Gutenberg University Mainz specializing in medicine, hepatology, and liver physiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	53	5.3K
2	Health Sciences	18	22	2.2K
3	Public Health	9	9	478
4	Nursing	1	1	32
5	Social Sciences	1	1	10

Jörn M. Schattenberg

190

Publications

18.8K

Citations

H-Index

Page 1

	Year	Citations
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030 Chris Estes, Quentin M. Anstee, M. Arias, Journal of Hepatology	2018	1.9K
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, New England Journal of Medicine	2024	1.4K
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
NASH limits anti-tumour surveillance in immunotherapy-treated HCC Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, Nature	2021	1.2K
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis Stuart McPherson, Timothy Hardy, Jean‐François Dufour, The American Journal of Gastroenterology	2016	844
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH Sven Francque, Pierre Bédossa, Vlad Ratziu, New England Journal of Medicine	2021	655
Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆ Quentin M. Anstee, Rebecca Darlay, Simon Cockell, Journal of Hepatology	2020	493
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue, Journal of Hepatology FibrosisHepatologyLiver PhysiologyClinical TrialsPathology	2020	438
Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis Olivier Govaere, Simon Cockell, Dina Tiniakos, Science Translational Medicine	2020	416
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial Rohit Loomba, Manal F. Abdelmalek, Matthew J. Armstrong, The Lancet. Gastroenterology & hepatology Placebo-controlled Phase 2HepatologyLiver PhysiologyPharmacologyPharmacotherapy	2023	413

Page 1